NICE welcomes new topic referral
The National Institute for Health and Clinical Excellence (NICE) welcomes the referral of additional topics by the Secretary of State for Health for its forward work programme, in line with the national priorities established for the NHS.
Topics include minded referrals for the technology appraisals programme on the treatment of chronic hepatitis B, and advanced and metastatic melanoma.
Public health guidance referred includes prevention of cardiovascular disease at the population level, and clinical guidelines referred include recognition and initial management of ovarian cancer, and recognition and diagnosis of Coeliac disease in adults.
Below is a full list of the topics that have been referred:
4 clinical guidelines on:
- recognition and initial management of ovarian cancer
- management of alcohol dependence
- diagnosis, prevention and management of delirium
- management of stable angina
1 short clinical guideline on:
- recognition and diagnosis of Coeliac disease in adults
3 topics for public health guidance on:
- prevention of unintentional injury in children under 15
- prevention of cardiovascular disease at the population level
- children in care
Minded referral topics for the technology appraisal programme:
12 technologies for appraisal as part of NICE's rapid single technology appraisal (STA) programme on:
- sorafenib for advanced hepatocellular carcinoma
- dasatinib for acute lymphoblastic leukaemia
- nilotinib for acute lymphoblastic leukaemia
- eltrombopag for refractory chronic immune (idiopathic) thrombocytopenic purpura
- AMG 531 for refractory chronic immune (idiopathic) thrombocytopenic purpura
- abatacept for juvenile idiopathic arthritis
- tenofovir for chronic hepatitis B
- xaliproden for Alzheimer's disease
- prasugrel for acute coronary artery syndromes with percutaneous coronary intervention
- detemir for type 1 diabetes mellitus temozolomide for advanced and metastatic melanoma
- liposomal muramyl tripetide phosophatidyl ethanolamine as an addition to adjuvant chemotherapy for newly diagnosed, non-metastatic, resectable osteosarcoma
3 technology for appraisals as part of NICE's multiple technology appraisal (MTA) programme on:
- dasatinib and nilotinib for imatinib-resistant chronic myeloid leukaemia
- topotecan for relapsed small cell lung cancer
- adalimumab and etanercept for polyarticular juvenile arthritis (including a review of TA35).
